Ceradyne (CRDN) announced that its preliminary sales figure for 2009 is approximately $401 million. These full year preliminary results compare to the guidance given on October 27, 2009 of sales in a range of $410 million to $415 million. The company noted that full year earnings are estimated to meet or slightly exceed the current guidance of approximately $0.60 per share which do not include the impact of restructuring and impairment charges for all of 2009 of approximately $0.55 per share.
Further, the company reiterated its 2010 guidance, initially provided on October 27, 2009, of a sales range of $380 million to $430 million and an earnings range of $0.60 to $1.05 per share.
Analysts expect the company to report earnings of $0.75 per share, on revenues of $391.01 million. Analysts' estimates typically exclude special items.
For comments and feedback: editorial@rttnews.com